Written notice to California Attorney General of proposed transaction with St. Mary Medical Center, LLC.

June 7, 2021

Share this Article
Facebook
Twitter
LinkedIn

Providence St. Mary Medical Center provided written notice to the California Attorney General of its proposed transaction with St. Mary Medical Center, LLC pursuant to California Corporations Code Section 5920.

The terms of the proposed transaction are set forth in the written notice to the Attorney General.

A copy of the written notice is available online for viewing or download by CLICKING HERE.

A copy of the supplemental information provided to the Attorney General in connection with the written notice is available online for viewing or download by CLICKING HERE.

A copy of the written notice is available for public inspection during normal business hours (8 a.m. to 5 p.m.) at the hospital location listed below:

St. Mary's Administration Building, 16071 Kasota Road, Apple Valley, 92307.

School’s out for summer! 5 ways for kids to keep mental health a priority during summer break

Help is Here has gathered some strategies for kids and families to keep mental health a top priority during...

Providence cancer research featured at global oncology conference

Researchers at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute, will join...

Most Recent Articles

Growing hope

Written notice to California Attorney General of proposed transaction with St. Mary Medical Center, LLC.

Previous Article

Next Article

Most Recent Articles

When a stroke robbed Lauren of her balance, the team on 4K – Providence Acute Rehabilitation Center – helped her regain what she lost with a little help from sunflowers, marigolds and little bugs.

The bariatric programs at Providence Little Company of Mary’s San Pedro and Torrance locations offer effective, long-term weight-loss solutions.

Providence South Division Cancer Institute earns national recognition as a top cancer program

Hospital program the only one recognized in Greater L.A. Area

More than 2,000 years ago, Hippocrates—the father of modern medicine—suggested that all diseases begin in the gut. With mounting evidence showing a connection between gut health and everything from au

Grounding allows us to use the earth’s negative electric charge to stabilize and rebalance our body’s accumulated positive charges. Contact with the vast supply of electrons on the earth’s surface—thi

Despite the sometimes dramatic improvements that have been made in other cancers, lung cancer survival has only slightly improved over the past several decades. Fortunately, that’s beginning to change

Rob Sears had been troubled by an increasingly erratic heartbeat for years. He finally found help from Dr. Shephal Doshi and a leading-edge minimally invasive procedure.

A special request for our patients and visitors – Farsi and Spanish translation further below:

R. Bryan Bell, M.D., D.D.S., FACS, FRCS(Ed) has accepted the roles of executive medical director of Providence Cancer Institute and director of the Earle A. Chiles Research Institute.

The team at the Adult and Pediatric Cochlear Implant Program, Dr. Courtney Voelker and Dr. Rebecca Lewis, restored Father Timothy McGowan’s hearing so he could get back to the work he loves.

Kadlec offering Prevention4ME for detection of breast and other cancers.

The annual SITC meeting brings together cancer immunotherapy researchers with a goal to advance science, discover breakthroughs and educate the world on cancer immunotherapy.

In 2023, Providence Alaska contributed $265,000 to Catholic Social Services’ Medical Respite program, which provides recuperative living quarters for patients experiencing homelessness.

Learn why a proposed FSED is not right for our community.

New study evaluates a type of CAR T-cell therapy called liso-cel. Researchers will collect data from multiple groups in a study that may give patients hope for long-term remission and quality of life.

Explore promising clinical trials at Providence Cancer Institute that are investigating immunotherapy for early-stage TNBC and high-risk, HR-positive breast cancer.